Disease Domain | Count |
---|---|
Infectious Diseases | 1 |
Endocrinology and Metabolic Disease | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Synthetic peptide | 1 |
Bacteriophage therapy | 1 |
Top 5 Target | Count |
---|---|
50S subunit x PRDX3(50S ribosomal subunit x peroxiredoxin 3) | 1 |
Target |
Mechanism 50S subunit inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jul 2024 |
Sponsor / Collaborator Hershey Medical Center [+10] |
Start Date01 May 2024 |
Sponsor / Collaborator |
Start Date01 May 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Thiostrepton ( 50S subunit x PRDX3 ) | Malignant Pleural Effusion More | Phase 2 Clinical |
AmpliPhage-004 | Clostridium Infections More | Preclinical |